News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioBehavioral Diagnostics Reels in $5.2 Million in Stock Sale


6/4/2012 8:41:22 AM

Philadelphia Business Journal by John George, Senior Reporter

BioBehavioral Diagnostics Co. raised $5.2 million in a private stock sale, according to documents filed with the Securities & Exchange Commission.

The Plymouth Meeting, Pa., company had developed and markets a tool —originally incorporated into a kiosk-like setup — that objectively measures brain functions to assist health-care providers diagnose attention-deficit hyperactivity disorder.

Last year, I wrote about the BioBehavioral Diagnostic’s development of a portable version of its Quotient ADHD System that is designed to take up less space in an office and be taken to different locations.

The system involves patients taking a 15- to 20-minute test designed to measure inattention, or the ability to focus; hyperactivity, the inability to sit still; and impulsivity, or acting without thinking.

Those factors are key elements used in the diagnosis of ADHD, a condition that affects nearly 10 million children, adolescents and adults in the United States.

The test consists of flashing images of stars on a screen. Patients are asked to hit the space bar when certain types of stars appear, and do nothing when other types of stars are shown. Reflectors worn on a headband and around the shins measure the results.

BioBehavioral Diagnostics is led by Byron Hewett, chairman and CEO.

The equity financing was disclosed in a filing provided to the Philadelphia Business Journal by FormsD.com.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES